Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1617SXK

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 3	MAR 16	CASREACT coverage extended
NEWS 4	MAR 20	MARPAT now updated daily
NEWS 5	MAR 22	LWPI reloaded
NEWS 6	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS 7	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS 8	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS 9	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS 10	APR 30	CA/CAplus enhanced with 1870-1889 U.S. patent records
NEWS 11	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS 12	MAY 01	New CAS web site launched
NEWS 13	MAY 08	CA/CAplus Indian patent publication number format defined
NEWS 14	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 15	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS 16	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS 17	MAY 21	CA/CAplus enhanced with additional kind codes for German patents
NEWS 18	MAY 22	CA/CAplus enhanced with IPC reclassification in Japanese patents
NEWS 19	JUN 27	CA/CAplus enhanced with pre-1967 CAS Registry Numbers
NEWS 20	JUN 29	STN Viewer now available
NEWS 21	JUN 29	STN Express, Version 8.2, now available
NEWS 22	JUL 02	LEMBASE coverage updated
NEWS 23	JUL 02	LMEDLINE coverage updated
NEWS 24	JUL 02	SCISEARCH enhanced with complete author names
NEWS 25	JUL 02	CHEMCATS accession numbers revised
NEWS 26	JUL 02	CA/CAplus enhanced with utility model patents from China

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:41:23 ON 13 JUL 2007

=>
=> file reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 13:41:33 ON 13 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 12 JUL 2007 HIGHEST RN 942260-92-6
DICTIONARY FILE UPDATES: 12 JUL 2007 HIGHEST RN 942260-92-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s 257892-33-4
L1 1 257892-33-4
(257892-33-4/RN)

=> d str cn

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

CN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-

fluorophenyl)methyl]-5-hydroxy-α-oxo- (CA INDEX NAME)
OTHER NAMES:
CN AWD 12-281
CN GW 842470

=> file caplus medline embase biosis
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 2.85 3.06

FILE 'CAPLUS' ENTERED AT 13:42:50 ON 13 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 13:42:50 ON 13 JUL 2007

FILE 'EMBASE' ENTERED AT 13:42:50 ON 13 JUL 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 13:42:50 ON 13 JUL 2007
Copyright (c) 2007 The Thomson Corporation

=> s 257892-33-4 or AWD 12-281
L2 111 257892-33-4 OR AWD 12-281

=> dup rem L2
PROCESSING COMPLETED FOR L2
L3 80 DUP REM L2 (31 DUPLICATES REMOVED)

=> s skin disease
L4 134945 SKIN DISEASE

=> s L3 and (AY<2003 or PY<2003 or PRY<2003)
'2003' NOT A VALID FIELD CODE
'2003' NOT A VALID FIELD CODE
2 FILES SEARCHED...
'2003' NOT A VALID FIELD CODE
'2003' NOT A VALID FIELD CODE
'2003' NOT A VALID FIELD CODE
'2003' NOT A VALID FIELD CODE
L5 36 L3 AND (AY<2003 OR PY<2003 OR PRY<2003)

=> s topical
L6 261595 TOPICAL

=> s L5 and L6
L7 5 L5 AND L6

=> d 1-5 L7 ibib abs

L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:203704 CAPLUS
DOCUMENT NUMBER: 140:229455
TITLE: Combination of glucocorticoids and PDE-4-inhibitors for treating respiratory diseases, allergic diseases, asthma and COPD
INVENTOR(S): Locher, Mathias; Hermann, Robert
PATENT ASSIGNEE(S): Viatris G.m.b.H. & Co. K.-G., Germany
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004019984	A1	20040311	WO 2003-EP8607		20030804 <--
W: AU, BR, CA, CN, CO, CZ, GE, HR, ID, IL, IN, JP, KR, LT, LV, MD, MK, MX, NO, NZ, PL, SG, UA, US, UZ, YU, ZA					
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR					
CA 2492645	A1	20040311	CA 2003-2492645		20030804 <--
AU 2003255365	A1	20040319	AU 2003-255365		20030804 <--
EP 1526870	A1	20050504	EP 2003-790851		20030804 <--
EP 1526870	B1	20070502			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, TR, BG, CZ, EE, HU, SK					
CN 1674939	A	20050928	CN 2003-819057		20030804 <--
JP 2005539042	T	20051222	JP 2004-531853		20030804 <--
AT 361076	T	20070515	AT 2003-790851		20030804 <--
US 2005288265	A1	20051229	US 2005-523802		20050209 <--
IN 2005KN00155	A	20060421	IN 2005-KN155		20050209 <--
NO 2005001212	A	20050308	NO 2005-1212		20050308 <--
PRIORITY APPLN. INFO.:			DE 2002-10236688	A	20020809 <--
			WO 2003-EP8607	W	20030804

AB The invention relates to a novel combination of a glucocorticoid, especially loteprednol, and at least one phosphodiesterase-4 inhibitor (PDE-4-inhibitor), especially hydroxyindole-derivative N-(3,5-dichloropyridine-4-yl)-2-[1-(4-fluorbenzyl)-5-hydroxyindole-3-yl]-2-oxoacetamide, for a simultaneous, sequential or sep. administration in the treatment of respiratory diseases, allergic diseases, asthma and chronic obstructive pulmonary diseases (COPD). Formulation of glucocorticoids and PDE-4-inhibitors can be prepared sep. and applied at the same time or at different times during the day; also combinations can be formulated.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:60309 CAPLUS
DOCUMENT NUMBER: 140:105273
TITLE: Topical treatment of skin diseases
INVENTOR(S): Rundfeldt, Chris; Kietzmann, Manfred; Hoppmann, Joachim; Baeumer, Wolfgang; Kuss, Hildegard; Hoefgen, Norbert
PATENT ASSIGNEE(S): Elbion AG, Germany
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004006920	A1	20040122	WO 2003-EP7514	20030710 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				

FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004038958	A1	20040226	US 2003-611649		20030701 <--
CA 2492093	A1	20040122	CA 2003-2492093		20030710 <--
AU 2003254332	A1	20040202	AU 2003-254332		20030710 <--
BR 2003012696	A	20050426	BR 2003-12696		20030710 <--
EP 1531818	A1	20050525	EP 2003-763810		20030710 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
CN 1681500	A	20051012	CN 2003-821520		20030710 <--
JP 2005537262	T	20051208	JP 2004-520586		20030710 <--
NZ 537482	A	20060929	NZ 2003-537482		20030710 <--
ZA 2005000108	A	20050223	ZA 2005-108		20050106 <--
NO 2005000718	A	20050401	NO 2005-718		20050210 <--
PRIORITY APPLN. INFO.:			US 2002-395221P	P	20020711 <--
			WO 2003-EP7514	W	20030710

OTHER SOURCE(S): MARPAT 140:105273

AB The present invention relates to a method for the treatment of an inflammatory and/or allergic skin disease comprising topically administering a substituted hydroxy indole which is a phosphodiesterase 4 inhibitor. Examples are provided of the topical effectiveness of AWD 12-281 and cilomilast in dermal immunol. inflammation.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:495906 CAPLUS

DOCUMENT NUMBER: 138:117605

TITLE: Effects of the phosphodiesterase 4 inhibitors SB 207499 and AWD 12-281 on the inflammatory reaction in a model of allergic dermatitis

AUTHOR(S): Baumer, Wolfgang; Gorr, Gilbert; Hoppmann, Joachim; Ehinger, Andreas M.; Ehinger, Britt; Kietzmann, Manfred

CORPORATE SOURCE: Toxicology and Pharmacy, Department of Pharmacology, School of Veterinary Medicine, Hanover, 30559, Germany

SOURCE: European Journal of Pharmacology (2002), 446(1-3), 195-200
CODEN: EJPHAZ; ISSN: 0014-2999

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The inhibitors of the phosphodiesterase 4, SB 207499 (cilomilast, c-4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)-r-L-cyclohexane carboxylic acid) and AWD 12-281 (N-(3,5-dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxyindole-3-yl]glyoxylic acid amide) were tested in a model of allergic dermatitis in mice. To obtain an allergic dermatitis, BALB/c mice were sensitized to toluene-2,4-diisocyanate. The allergic reaction was challenged by topical administration of toluene-2,4-diisocyanate onto the mice ears. Before challenge, two groups of mice were treated topically (ear skin) with SB 207499 or AWD 12-281. There was a significant ear swelling in toluene-2,4-diisocyanate-challenged mice ears 4, 8, 16, 24 and 48 h after challenge. SB 207499 and AWD 12-281 inhibited this swelling significantly 8, 16, 24 and 48 h after the challenge. For biochem. parameters and histol., ears were sampled from mice sacrificed 4, 8 and 16 h after the challenge. In homogenized tissue, SB 207499 and AWD 12-281 inhibited significantly the secretion of interleukin 1β induced by toluene-2,4-diisocyanate 4 and 8 h after challenge. The cell influx (granulocytes) observed in the toluene-2,4-diisocyanate-challenged mice 8 and 16 h after challenge was nearly abolished by AWD 12-

281 and SB 204799.
REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:420229 CAPLUS
DOCUMENT NUMBER: 138:18980
TITLE: AWD 12-281
AUTHOR(S): Kuss, H.; Hofgen, N.; Egerland, U.; Heer, S.; Marx, D.; Szelenyi, I.; Schupke, H.; Gasparic, A.; Olbrich, M.; Hempel, R.; Hartenhauer, H.; Krone, D.; Berthold, K.; Kronbach, T.; Rundfeldt, C.
CORPORATE SOURCE: Arzneimittelwerk Dresden GmbH, Radebeul, D-01445, Germany
SOURCE: Drugs of the Future (2002), 27(2), 111-116
CODEN: DRFUD4; ISSN: 0377-8282
PUBLISHER: Prous Science
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review. Airway diseases such as bronchial asthma and chronic obstructive pulmonary disease (COPD) are chronic inflammatory diseases whose prevalence is increasing. Current research concerned with developing effective treatments for these conditions have focused on the search for alternatives to the standard corticosteroid antiinflammatory therapy. Selective phosphodiesterase 4 (PDE4) inhibitors have received a considerable amount of attention due to their ability to suppress the functions of several cell types involved in allergic and inflammatory disorders. The selective PDE4 inhibitor AWD 12-281 is the result of a pharmacophore-based synthesis program wherein the optimization process was supported by ligand-based drug design methods. AWD 12-281 was selected for further development for its high affinity and selectivity for the human PDE4 isoenzyme and due to its potent activity and excellent tolerability in models of allergic rhinitis, asthma and COPD, especially after topical treatment.
REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 5 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 2000413538 EMBASE
TITLE: Animal models of allergic rhinitis.
AUTHOR: Szelenyi I.; Marx D.; Jahn W.
CORPORATE SOURCE: Dr. I. Szelenyi, Pulmonary Pharmacology (BF-FP2), Meissnerstr. 191, 01445 Radebeul, Germany. stefan.szelenyi@astamedica.de
SOURCE: Arzneimittel-Forschung/Drug Research, (2000) Vol. 50, No. 11, pp. 1037-1042. .
Refs: 44
ISSN: 0004-4172 CODEN: ARZNAD
COUNTRY: Germany
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 011 Otorhinolaryngology
026 Immunology, Serology and Transplantation
030 Pharmacology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English; German
ENTRY DATE: Entered STN: 14 Dec 2000
Last Updated on STN: 14 Dec 2000
AB Actively sensitized Brown Norway rats and guinea pig are useful species for studying drug effects on symptoms of experimental rhinitis. Even if not all symptoms of human rhinitis can be induced and detected in the same animal species, the predictablity of methods generally used is well

acceptable. In the present review, advantages and disadvantages of experimental methods of rhinitis will be discussed.

=> s dermal or skin
L8 1414890 DERMAL OR SKIN

=> s L3 and L8
L9 13 L3 AND L8

=> d 1-13 ibib abs

L9 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:331227 CAPLUS
DOCUMENT NUMBER: 146:308239
TITLE: Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis
AUTHOR(S): Baeumer, Wolfgang; Hoppmann, Joachim; Rundfeldt, Chris; Kietzmann, Manfred
CORPORATE SOURCE: Department of Pharmacology, Toxicology, and Pharmacy, Foundation, University of Veterinary Medicine Hannover, Hannover, D-30559, Germany
SOURCE: Inflammation & Allergy: Drug Targets (2007), 6(1), 17-26
CODEN: IADTAQ; ISSN: 1871-5281
PUBLISHER: Bentham Science Publishers Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review. The phosphodiesterase (PDE) 4 is the predominant cAMP degrading enzyme in a variety of inflammatory cells including eosinophils, neutrophils, macrophages, T cells and monocytes. In addition, this enzyme is expressed in non-immune cells such as keratinocytes and fibroblasts. Highly selective PDE4 inhibitors are currently under evaluation for the treatment of asthma and/or chronic obstructive pulmonary disease. Due to the broad anti-inflammatory/immunomodulatory action of PDE4 inhibitors, it has been proposed that PDE4 inhibitors might also be efficacious for skin disorders such as atopic dermatitis. Consequently, PDE4 inhibitors including cilomilast and AWD 12-281 have been tested in several models of allergic and irritant skin inflammation. These PDE4 inhibitors displayed strong anti-inflammatory action in models of allergic contact dermatitis in mice, in the arachidonic acid induced skin inflammation in mice and in ovalbumin sensitized guinea pigs. The determination of cytokines in skin homogenates revealed that both Th1 as well as Th2 cytokines are suppressed by PDE4 inhibitors, indicating an anti-inflammatory activity in both the Th2 dominated acute phase as well as the Th1 dominated chronic phase of atopic dermatitis. Due to the suppression of Th1 cytokines, activity can also be expected in psoriasis. Results of early clin. trials with both topically (cipamfylline, CP80,633) and systemically (CC-10004) active PDE4 inhibitors demonstrated efficacy in atopic dermatitis and in the case of CC-10004, also in psoriasis. AWD 12-281 (GW 842470) is currently under clin. evaluation for the topical treatment of atopic dermatitis. Results concerning clin. efficacy of this potent and selective PDE4 inhibitor are anxiously awaited.
REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1256669 CAPLUS
DOCUMENT NUMBER: 146:20293
TITLE: Novel medicament combinations for the treatment of respiratory diseases
INVENTOR(S): Pieper, Michael P.; Schnapp, Andreas; Nickolaus, Peter

PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany
SOURCE: U.S. Pat. Appl. Publ., 33pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006270667	A1	20061130	US 2006-420872	20060530
WO 2006128847	A2	20061207	WO 2006-EP62683	20060529
WO 2006128847	A3	20070426		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: EP 2005-104702 A 20050531
OTHER SOURCE(S): MARPAT 146:20293

AB The present invention relates to new medicament combinations which contain in addition to one or more, preferably one, betamimetic, at least one anticholinergic and at least one PDE-IV inhibitor processes for preparing them and their use as pharmaceutical compns.

L9 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:365169 CAPLUS
DOCUMENT NUMBER: 144:419682
TITLE: Pharmaceutical compositions containing phosphodiesterase IV inhibitors and immunosuppressants
INVENTOR(S): Harada, Daisuke; Kobayashi, Katsuya; Manabe, Haruhiko; Ohshima, Etsuo
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006041120	A1	20060420	WO 2005-JP18854	20051013

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

CA 2584261	A1	20060420	CA 2005-2584261	20051013

PRIORITY APPLN. INFO.: JP 2004-299104 A 20041013

JP 2005-113265 A 20050411
WO 2005-JP18854 W 20051013

AB This invention relates to pharmaceutical compns. for the prevention and treatment of chronic skin diseases, comprising (a) a phosphodiesterase (PDE)-IV inhibitor or a pharmacol. acceptable salt thereof and (b) an immunosuppressant, which are administered simultaneously or sep. with an interval. For example, tablets were formulated containing 2-(3,5-dichloro-4-pyridinyl)-1-(7-methoxyspiro[1,3-benzodioxole-2,1'-cyclopentan]-4-yl)ethanone (PDE-IV inhibitor) 20, tacrolimus (immunosuppressant) 20, lactose 123.4, starch 20, hydroxypropyl cellulose 6, and Mg stearate 0.6 mg per tablet.

REFERENCE COUNT: 113 THERE ARE 113 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:364924 CAPLUS
DOCUMENT NUMBER: 144:398341
TITLE: Phosphodiesterase IV inhibitor and steroid combinations for the treatment of chronic skin disease
INVENTOR(S): Harada, Daisuke; Kobayashi, Katsuya; Manabe, Haruhiko; Ohshima, Etsuo
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006041121	A1	20060420	WO 2005-JP18855	20051013
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA 2584169	A1	20060420	CA 2005-2584169	20051013

PRIORITY APPLN. INFO.: JP 2004-299103 A 20041013
JP 2005-113264 A 20050411
WO 2005-JP18855 W 20051013

AB It is intended to provide a remedy and/or a preventive for a chronic skin disease which comprises (a) a phosphodiesterase (PDE)-IV inhibitor or a pharmacol. acceptable salt thereof and (b) a steroid drug, which are administered simultaneously or sep. at an interval. For example, tablets were formulated containing 2-(3,5-dichloro-4-pyridinyl)-1-(7-methoxyspiro[1,3-benzodioxole-2,1'-cyclopentan]-4-yl)ethanone 50, prednisolone 20, lactose 123.4, starch 20, hydroxypropyl cellulose 6, and Mg stearate 0.6 mg per tablet.

REFERENCE COUNT: 128 THERE ARE 128 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:226501 CAPLUS

DOCUMENT NUMBER: 144:267237
TITLE: The phosphodiesterase 4 inhibitor AWD 12-281 is active in a new guinea-pig model of allergic skin inflammation predictive of human skin penetration and suppresses both Th1 and Th2 cytokines in mice
AUTHOR(S): Hoppmann, Joachim; Baeumer, Wolfgang; Galetzka, Christin; Hoefgen, Norbert; Kietzmann, Manfred; Rundfeldt, Chris
CORPORATE SOURCE: Department of Pharmacology, elbion AG, Radebeul, D-01445, Germany
SOURCE: Journal of Pharmacy and Pharmacology (2005), 57(12), 1609-1617
CODEN: JPPMAB; ISSN: 0022-3573
PUBLISHER: Pharmaceutical Press
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The selective phosphodiesterase 4 (PDE4) inhibitor AWD 12-281 is structurally optimized for topical administration. It has potent effects in models of lung inflammation if administered as a dry powder inhalation. It has also demonstrated its anti-inflammatory property in a mouse model of cutaneous inflammation after topical administration. The aim of this study was to evaluate whether AWD 12-281 may be capable of penetrating human skin. Therefore a new guinea-pig model of allergic skin inflammation had to be developed. In ovalbumin-sensitized guinea-pigs, intracutaneous administration of ovalbumin results in a rapid development of allergic skin wheals. Topically administered AWD 12-281 was capable of reducing the development of wheals, indicating that this compound can penetrate the stratum corneum of guinea-pig skin as a predictor of human skin penetration. A secondary aim was the evaluation of a T cell subtype preference of AWD 12-281 since PDE4 inhibitors are said to preferentially inhibit Th2-type cytokines. Therefore, the effects of AWD 12-281 on a broad spectrum of Th1- and Th2-type cytokines were studied in tissue homogenates after allergen challenge in sensitized mice and in supernatants of anti CD3/anti-CD28-stimulated peripheral blood mononuclear cells (PBMCs). In both models, AWD 12-281 suppressed both T cell subtype cytokines indicating a broad spectrum activity of AWD 12-281. A further issue was to determine the duration of action and the concentration-response relation of the topical activity of AWD 12-281 using a model of acute local inflammation - the arachidonic-acid-induced mouse ear edema. The compound exhibited a dose-dependent effect with a minimally effective concentration of 0.3%; after repeated administration the minimally effective concentration was 0.03%. A single administration of a 3% solution resulted in significant suppression of inflammation even 48 h after treatment. In conclusion, our results indicate that AWD 12-281 is a very promising drug candidate not only for the treatment of lung inflammation using inhalative administration but also for the treatment of atopic dermatitis.
REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:149262 CAPLUS
DOCUMENT NUMBER: 144:239931
TITLE: Pharmaceutical compositions for the treatment of respiratory and gastrointestinal disorders
INVENTOR(S): Jung, Birgit; Himmelsbach, Frank
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma Gmbh & Co. KG

SOURCE: PCT Int. Appl., 321 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006015775	A2	20060216	WO 2005-EP8385	20050803
WO 2006015775	A3	20070518		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US 2006035893	A1	20060216	US 2005-189643	20050726
CA 2575541	A1	20060216	CA 2005-2575541	20050803
EP 1784224	A2	20070516	EP 2005-773706	20050803
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				

PRIORITY APPLN. INFO.: EP 2004-18808 A 20040807
WO 2005-EP8385 W 20050803

OTHER SOURCE(S): MARPAT 144:239931

AB The present invention relates to novel pharmaceutical compns. comprising at least 1 EGFR kinase inhibitor and at least one addnl. active compound selected from β-2 mimetics, steroids, PDE-IV inhibitors, p38 MAP kinase inhibitors, NK1 antagonists and endothelin-antagonists, processes for preparing the compns. and the use thereof as drugs in the treatment of respiratory or gastrointestinal complaints, as well as inflammatory diseases of the joints, the skin or the eyes. Thus, an inhalable powder contained an EGFR kinase inhibitor 150, formoterol fumarate dihydrate 50, and lactose 12,300 mg/capsule.

L9 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1155523 CAPLUS
DOCUMENT NUMBER: 143:416252
TITLE: Novel medicament combinations for the treatment of respiratory diseases
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany
SOURCE: U.S. Pat. Appl. Publ., 50 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005239778	A1	20051027	US 2005-109094	20050419
DE 102004019540	A1	20051110	DE 2004-102004019540	20040422
DE 102004052987	A1	20060504	DE 2004-102004052987	20041103
AU 2005235419	A1	20051103	AU 2005-235419	20050418
CA 2559699	A1	20051103	CA 2005-2559699	20050418
WO 2005102349	A1	20051103	WO 2005-EP4073	20050418
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT; LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1781298 A1 20070509 EP 2005-739576 20050418

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR

NO 2006005060 A 20061121 NO 2006-5060 20061102

PRIORITY APPLN. INFO.: DE 2004-102004019540A 20040422
US 2004-578542P P 20040610
DE 2004-102004052987A 20041103
EP 2005-2496 A 20050207
WO 2005-EP4073 W 20050418

OTHER SOURCE(S): MARPAT 143:416252

GI



I

AB The present invention relates to a pharmaceutical composition comprising one or more compds. of formula I wherein n denotes 1 or 2; R1 denotes hydrogen, halogen, C1-C4-alkyl or -O-C1-C4-alkyl; R2 denotes hydrogen, halogen, C1-C4-alkyl or -O-C1-C4-alkyl; R3 denotes C1-C4-alkyl, OH, halogen, -O-C1-C4-alkyl, -O-C1-C4-alkylene-COOH, -O-C1-C4-alkylene-CO-O-C1-C4-alkyl, and at least one other active substance for the treatment of respiratory diseases. The second active substance can by an anticholinergic, a phosphodiesterase IV inhibitor, a steroid, a LTD4 antagonist or an EGFR inhibitor.

L9 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:60309 CAPLUS
DOCUMENT NUMBER: 140:105273
TITLE: Topical treatment of skin diseases
INVENTOR(S): Rundfeldt, Chris; Kietzmann, Manfred; Hoppmann, Joachim; Baeumer, Wolfgang; Kuss, Hildegard; Hoefgen, Norbert
PATENT ASSIGNEE(S): Elbion AG, Germany
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004006920	A1	20040122	WO 2003-EP7514	20030710

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004038958	A1	20040226	US 2003-611649		20030701
CA 2492093	A1	20040122	CA 2003-2492093		20030710
AU 2003254332	A1	20040202	AU 2003-254332		20030710
BR 2003012696	A	20050426	BR 2003-12696		20030710
EP 1531818	A1	20050525	EP 2003-763810		20030710
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
CN 1681500	A	20051012	CN 2003-821520		20030710
JP 2005537262	T	20051208	JP 2004-520586		20030710
NZ 537482	A	20060929	NZ 2003-537482		20030710
ZA 2005000108	A	20050223	ZA 2005-108		20050106
NO 2005000718	A	20050401	NO 2005-718		20050210
PRIORITY APPLN. INFO.:			US 2002-395221P	P	20020711
			WO 2003-EP7514	W	20030710

OTHER SOURCE(S): MARPAT 140:105273

AB The present invention relates to a method for the treatment of an inflammatory and/or allergic skin disease comprising topically administering a substituted hydroxy indole which is a phosphodiesterase 4 inhibitor. Examples are provided of the topical effectiveness of AWD 12-281 and cilomilast in dermal immunol. inflammation.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:695438 CAPLUS

DOCUMENT NUMBER: 140:87294

TITLE: AWD 12-281, a highly selective phosphodiesterase 4 inhibitor, is effective in the prevention and treatment of inflammatory reactions in a model of allergic dermatitis

AUTHOR(S): Baeumer, Wolfgang; Gorr, Gilbert; Hoppmann, Joachim; Ehinger, Andreas M.; Rundfeldt, Chris; Kietzmann, Manfred

CORPORATE SOURCE: Department of Pharmacology, Toxicology and Pharmacy, School of Veterinary Medicine, Hannover, D-30559, Germany

SOURCE: Journal of Pharmacy and Pharmacology (2003), 55(8), 1107-1114
CODEN: JPPMAB; ISSN: 0022-3573

PUBLISHER: Pharmaceutical Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB AWD 12-281 (N-(3,5-dichloro-4-pyridinyl)-2-[1-(4-fluorobenzyl)-5-hydroxy-1H-indol-3-yl]-2-oxoacetamide), a phosphodiesterase 4 inhibitor, which is optimized for topical administration, was tested in a model of allergic dermatitis in mice. To obtain an allergic dermatitis, BALB/c mice were sensitized to toluene-2,4-diisocyanate (TDI). The allergic reaction was challenged by topical administration of TDI onto the mice ears. AWD 12-281 was tested for its anti-inflammatory potential by oral, i.p. and topical administration. The phosphodiesterase 4 inhibitor, cilomilast (SB 207499), and/or the corticosteroid, diflorasone diacetate, were used as reference compds. Given orally and i.p. 2 h before as well as 5

and 24 h after TDI challenge, AWD 12-281 showed no, or only a transient inhibition of the allergen-induced ear swelling, whereas cilomilast significantly inhibited this ear swelling. Applied topically onto the ears before TDI challenge, AWD 12-281, cilomilast and diflorasone diacetate caused total inhibition of ear swelling 24 h after challenge, confirmed by a decrease of the pro-inflammatory cytokines interleukin-4, interleukin-6 and macrophage inhibitory protein-2. Administered topically after TDI challenge as therapeutic intervention, AWD 12-281 and diflorasone diacetate caused significant inhibition of ear swelling; cilomilast failed to do so. These results indicate that topically administered AWD 12-281 may be potent in the prevention and treatment of allergic/inflammatory skin diseases.

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 10 OF 13 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:495906 CAPLUS
DOCUMENT NUMBER: 138:117605
TITLE: Effects of the phosphodiesterase 4 inhibitors SB 207499 and AWD 12-281 on the inflammatory reaction in a model of allergic dermatitis
AUTHOR(S): Baumer, Wolfgang; Gorr, Gilbert; Hoppmann, Joachim; Ehinger, Andreas M.; Ehinger, Britt; Kietzmann, Manfred
CORPORATE SOURCE: Toxicology and Pharmacy, Department of Pharmacology, School of Veterinary Medicine, Hanover, 30559, Germany
SOURCE: European Journal of Pharmacology (2002), 446(1-3), 195-200
CODEN: EJPHAZ; ISSN: 0014-2999
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The inhibitors of the phosphodiesterase 4, SB 207499 (cilomilast, c-4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)-r-L-cyclohexane carboxylic acid) and AWD 12-281 (N-(3,5-dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxyindole-3-yl]glyoxylic acid amide) were tested in a model of allergic dermatitis in mice. To obtain an allergic dermatitis, BALB/c mice were sensitized to toluene-2,4-diisocyanate. The allergic reaction was challenged by topical administration of toluene-2,4-diisocyanate onto the mice ears. Before challenge, two groups of mice were treated topically (ear skin) with SB 207499 or AWD 12-281. There was a significant ear swelling in toluene-2,4-diisocyanate-challenged mice ears 4, 8, 16, 24 and 48 h after challenge. SB 207499 and AWD 12-281 inhibited this swelling significantly 8, 16, 24 and 48 h after the challenge. For biochem. parameters and histol., ears were sampled from mice sacrificed 4, 8 and 16 h after the challenge. In homogenized tissue, SB 207499 and AWD 12-281 inhibited significantly the secretion of interleukin 1β induced by toluene-2,4-diisocyanate 4 and 8 h after challenge. The cell influx (granulocytes) observed in the toluene-2,4-diisocyanate-challenged mice 8 and 16 h after challenge was nearly abolished by AWD 12-281 and SB 204799.

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 11 OF 13 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 2007223472 EMBASE
TITLE: Therapeutic benefit of PDE4 inhibitors in inflammatory diseases.

AUTHOR: Dastidar S.G.; Rajagopal D.; Ray A.
CORPORATE SOURCE: S.G. Dastidar, Ranbaxy Research Laboratories, Department of Pharmacology, New Drug Discovery Research, Gurgaon 122 001, India. sunanda.dastidar@ranbaxy.com
SOURCE: Current Opinion in Investigational Drugs, (2007) Vol. 8, No. 5, pp. 364-372. .
Refs: 101
ISSN: 1472-4472 CODEN: CIDREE
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 026 Immunology, Serology and Transplantation
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 5 Jun 2007
Last Updated on STN: 5 Jun 2007

AB Intracellular levels of cyclic nucleotides are closely regulated by distinct families of PDEs, which are responsible for the breakdown and degradation of cyclic nucleotides within cells. Type 4 PDEs have the potency to modulate the release of inflammatory mediators through cAMP-dependent and -independent mechanisms. Selective targeting of PDE4 is currently being investigated as a novel therapeutic approach in the treatment of inflammation-associated respiratory diseases such as asthma and COPD. The development of several PDE4 inhibitors, including roflumilast and cilomilast, reflects the success of this approach. In principle, therapeutic intervention of an inflammatory response by PDE4 inhibitors may be extended to other chronic inflammatory disease states such as psoriasis, rheumatoid arthritis and inflammatory bowel diseases (eg, Crohn's disease and ulcerative colitis). This review explores the feasibility of PDE4 inhibitors as a promising alternative for therapeutic intervention in systemic inflammation and inflammation-based disease. .COPYRGT. The Thomson Corporation.

L9 ANSWER 12 OF 13 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
ACCESSION NUMBER: 2003:307114 BIOSIS
DOCUMENT NUMBER: PREV200300307114
TITLE: The phosphodiesterase 4 inhibitors AWD 12 -281 and cilomilast exhibit different effectiveness in the prevention and treatment of inflammatory reactions in a model of allergic dermatitis.
AUTHOR(S): Baeumer, W. [Reprint Author]; Hoppmann, J.; Tschernig, T.; Seegers, U. [Reprint Author]; Rundfeldt, C.; Kietzmann, M. [Reprint Author]
CORPORATE SOURCE: Depts of Pharmacology, Toxicology and Pharmacy, School of Veterinary Medicine, 30559, Hannover, Germany
SOURCE: Naunyn-Schmiedeberg's Archives of Pharmacology, (March 2003) Vol. 367, No. Supplement 1, pp. R77. print.
Meeting Info.: 44th Spring Meeting of the Deutsche Gesellschaft fuer Experimentelle und Klinische Pharmakologie und Toxikologie and the 20th Meeting of the Gesellschaft fuer Umwelt-Mutationsforschung. Mainz, Germany. March 17-20, 2003.
ISSN: 0028-1298 (ISSN print).
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 2 Jul 2003
Last Updated on STN: 2 Jul 2003

L9 ANSWER 13 OF 13 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
ACCESSION NUMBER: 2001:297031 BIOSIS

DOCUMENT NUMBER: PREV200100297031
TITLE: Studies with AWD 12281 in the skin of sensitized mice.
AUTHOR(S): Ehinger, A. M. [Reprint author]; Gorr, G. [Reprint author]; Hoppmann, J. [Reprint author]; Telser, E. [Reprint author]; Kietzmann, M. [Reprint author]
CORPORATE SOURCE: Institut fuer Pharmakologie, Toxikologie und Pharmazie, Tieraerztliche Hochschule Hannover, Buenteweg 17, D-30559, Hannover, Germany
SOURCE: Naunyn-Schmiedeberg's Archives of Pharmacology, (2001) Vol. 363, No. 4 Supplement, pp. R85. print.
Meeting Info.: 42nd Spring Meeting of the German Society for Experimental and Clinical Pharmacology and Toxicology. Mainz, Germany. March 13-15, 2001. German Society for Experimental and Clinical Pharmacology and Toxicology.
CODEN: NSAPCC. ISSN: 0028-1298.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 20 Jun 2001
Last Updated on STN: 19 Feb 2002